RU2727474C2 - Виды комбинированной терапии для лечения рака - Google Patents

Виды комбинированной терапии для лечения рака Download PDF

Info

Publication number
RU2727474C2
RU2727474C2 RU2018109902A RU2018109902A RU2727474C2 RU 2727474 C2 RU2727474 C2 RU 2727474C2 RU 2018109902 A RU2018109902 A RU 2018109902A RU 2018109902 A RU2018109902 A RU 2018109902A RU 2727474 C2 RU2727474 C2 RU 2727474C2
Authority
RU
Russia
Prior art keywords
cancer
treatment
chlorophenyl
tumor
agents
Prior art date
Application number
RU2018109902A
Other languages
English (en)
Russian (ru)
Other versions
RU2018109902A (ru
RU2018109902A3 (enExample
Inventor
Реза Фатхи
Дрор БЕН-АШЕР
Даниелль АБРАМСОН
Original Assignee
Редхилл Байофарма Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редхилл Байофарма Лтд. filed Critical Редхилл Байофарма Лтд.
Publication of RU2018109902A publication Critical patent/RU2018109902A/ru
Publication of RU2018109902A3 publication Critical patent/RU2018109902A3/ru
Application granted granted Critical
Publication of RU2727474C2 publication Critical patent/RU2727474C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2018109902A 2015-10-06 2016-10-06 Виды комбинированной терапии для лечения рака RU2727474C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562237925P 2015-10-06 2015-10-06
US62/237,925 2015-10-06
PCT/IB2016/001526 WO2017060771A2 (en) 2015-10-06 2016-10-06 Combination therapies for treating cancer

Publications (3)

Publication Number Publication Date
RU2018109902A RU2018109902A (ru) 2019-11-07
RU2018109902A3 RU2018109902A3 (enExample) 2020-03-05
RU2727474C2 true RU2727474C2 (ru) 2020-07-21

Family

ID=58446480

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018109902A RU2727474C2 (ru) 2015-10-06 2016-10-06 Виды комбинированной терапии для лечения рака

Country Status (12)

Country Link
US (4) US9844540B2 (enExample)
EP (1) EP3359255B1 (enExample)
JP (1) JP6963545B2 (enExample)
KR (1) KR20180058716A (enExample)
CN (1) CN108136207A (enExample)
AU (1) AU2016336133B2 (enExample)
BR (1) BR112018003232A2 (enExample)
CA (1) CA2997671A1 (enExample)
HK (1) HK1259342A1 (enExample)
MX (1) MX382754B (enExample)
RU (1) RU2727474C2 (enExample)
WO (1) WO2017060771A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703307WA (en) * 2014-10-24 2017-05-30 Redhill Biopharma Ltd Therapy for inhibition of single-stranded rna virus replication
EP3612177A4 (en) 2017-04-21 2021-01-13 Lunella Biotech, Inc. TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY
CA3060510A1 (en) 2017-04-21 2018-10-25 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
JP6938682B2 (ja) 2017-05-19 2021-09-22 ルネラ・バイオテック・インコーポレーテッド アンチミトシン：癌幹細胞を根絶するためのミトコンドリア生合成の標的阻害薬
CU20190106A7 (es) 2017-06-26 2020-11-30 Lunella Biotech Inc Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
EP4324460A3 (en) 2017-09-15 2024-04-24 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
US20190134219A1 (en) * 2017-09-15 2019-05-09 Ampersand Biopharmaceuticals, Inc. Inhibition of spontaneous metastasis via protein inhibitors of cysteine proteases
CA3126818A1 (en) * 2019-01-16 2020-07-23 Apogee Biotechnology Corporation Combination of a sk2 inhibitor and an inhibitor of a checkpoint pathway, uses and pharmaceutical compositions therof
WO2020154716A1 (en) * 2019-01-26 2020-07-30 University Of Rochester Compositions and methods for treating prostate cancer
US11052073B1 (en) 2020-03-10 2021-07-06 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia
CN119700770A (zh) * 2025-01-09 2025-03-28 首都医科大学附属北京佑安医院 氯法齐明在制备修复肠黏膜或改善肠道菌群药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013723A1 (en) * 1998-07-20 2003-01-16 Wilex Ag Novel urokinase inhibitors
US20040067952A1 (en) * 2001-07-17 2004-04-08 Morris David Lawson Method and composition for treatment of cancer
WO2013041963A2 (en) * 2011-09-20 2013-03-28 Redhill Biopharma Ltd A composition and method for treating an autoimmune disease
US20140314878A1 (en) * 2012-08-30 2014-10-23 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2189001A1 (en) 1994-04-26 1995-11-02 Nobuhiro Narita Medicinal composition as a remedy for nonsmall cell lung cancer
AUPP437698A0 (en) 1998-06-30 1998-07-23 Baumgart, Karl Methods for treatment of coronary, carotid and other vascular disease
US6864264B1 (en) * 2002-08-20 2005-03-08 Gloria L. Anderson 1-adamantyl chalcones for the treatment of proliferative disorders
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE102004057195A1 (de) * 2004-11-26 2006-06-01 Wilex Ag Kristalline Modifikationen von N-Alpha-(2,4,6-Triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanin-4-ethoxycarbonylpiperazid und/oder Salzen davon
US20060142304A1 (en) 2004-12-27 2006-06-29 Michael Southall Method for treating or preventing pruritic and neurogenic skin disorders
US20060270631A1 (en) 2005-05-26 2006-11-30 Smith Charles D Methods for the treatment and prevention of angiogenic diseases
MX2007015863A (es) * 2005-06-17 2008-04-02 Apogee Biotechnology Corp Inhibidores de esfingosina cinasa.
TWI405756B (zh) * 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
US20080226624A1 (en) * 2007-03-07 2008-09-18 Wolfgang Schmalix Combined treatment of cancer by urokinase inhibition and a cytostatic anti-cancer agent for enhancing the anti-metastatic effect
PL2247291T3 (pl) * 2008-02-08 2019-05-31 Red Hill Biopharma Ltd Sposoby i kompozycje do leczenia nieswoistego zapalenia jelit
SG11201703307WA (en) * 2014-10-24 2017-05-30 Redhill Biopharma Ltd Therapy for inhibition of single-stranded rna virus replication

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013723A1 (en) * 1998-07-20 2003-01-16 Wilex Ag Novel urokinase inhibitors
US20040067952A1 (en) * 2001-07-17 2004-04-08 Morris David Lawson Method and composition for treatment of cancer
WO2013041963A2 (en) * 2011-09-20 2013-03-28 Redhill Biopharma Ltd A composition and method for treating an autoimmune disease
US20140314878A1 (en) * 2012-08-30 2014-10-23 James Sacchettini Compositions and methods for drug-sensitization or inhibition of a cancer cell

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
FRENCH K.J. et al. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2// The Journal of Pharmacology and Experimental Therapeutics, 08 Jan 2010, 333(1):129-139. *
FRORIEP D. et al. Activation of the anti-cancer agent upamostat by the mARC enzyme system// Xenobiotica. 2013 Sep;43(9):780-4. *
SAKAMOTO M. et al. Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer// Gan To Kagaku Ryoho. 1998 Dec;25(14):2259-66. *
SRI-PATHMANATHAN R.M. et al. Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung‐cancer cell line in vitro and in vivo//Int J Cancer. 1994 Mar 15;56(6):900-5. *
SRI-PATHMANATHAN R.M. et al. Clofazimine alters the energy metabolism and inhibits the growth rate of a human lung‐cancer cell line in vitro and in vivo//Int J Cancer. 1994 Mar 15;56(6):900-5. SAKAMOTO M. et al. Effect of clarithromycin treatment of natural killer cell activity in patients with advanced non-small cell lung cancer// Gan To Kagaku Ryoho. 1998 Dec;25(14):2259-66. FRORIEP D. et al. Activation of the anti-cancer agent upamostat by the mARC enzyme system// Xenobiotica. 2013 Sep;43(9):780-4. *

Also Published As

Publication number Publication date
JP2018533560A (ja) 2018-11-15
EP3359255B1 (en) 2025-12-24
US10946000B2 (en) 2021-03-16
US10463654B2 (en) 2019-11-05
EP3359255A4 (en) 2019-06-12
MX2018004309A (es) 2018-05-22
EP3359255A2 (en) 2018-08-15
US20200113881A1 (en) 2020-04-16
WO2017060771A2 (en) 2017-04-13
RU2018109902A (ru) 2019-11-07
US9844540B2 (en) 2017-12-19
AU2016336133A1 (en) 2018-03-15
BR112018003232A2 (pt) 2018-09-25
WO2017060771A3 (en) 2017-07-06
US11633385B2 (en) 2023-04-25
RU2018109902A3 (enExample) 2020-03-05
JP6963545B2 (ja) 2021-11-10
US20170095460A1 (en) 2017-04-06
US20210128538A1 (en) 2021-05-06
HK1259342A1 (zh) 2019-11-29
CA2997671A1 (en) 2017-04-13
CN108136207A (zh) 2018-06-08
AU2016336133B2 (en) 2021-02-25
MX382754B (es) 2025-03-13
US20180125831A1 (en) 2018-05-10
KR20180058716A (ko) 2018-06-01

Similar Documents

Publication Publication Date Title
US11633385B2 (en) Combination compositions for treatment of cancer
KR102356433B1 (ko) 치환된 아미노퓨린 화합물, 이의 조성물, 및 그것에 의한 치료 방법
JP5075927B2 (ja) 固形腫瘍を予防および治療するための方法および組成物
JP6257326B2 (ja) 神経因性疼痛におけるマロノニトリルアミドの使用
JP2015505313A (ja) 癌を治療するための併用療法
EA019919B1 (ru) Способ подавления роста или метастазирования ангиогенез-зависимой опухоли
TW201919616A (zh) 用於治療ｔ－ｐｌｌ的化合物
US20240366566A1 (en) Use of carbamate compound for prevention, alleviation or treatment of status epilepticus
US20260091021A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
JP6370801B2 (ja) 肝疾患または肝障害の治療のための使用および方法
CN115969975B (zh) Phgdh抑制剂在预防和/或治疗结直肠癌转移中的应用
WO2021048419A1 (en) Combination therapies comprising trametinib for the treatment of cholangiocarcinoma
JP4686704B2 (ja) 動脈瘤予防および／または治療剤
RU2436572C2 (ru) Комбинация ингибиторов гистондеацетилазы и излучения
JP2009108058A (ja) 抗リンパ腫組成物および方法
US20060009475A1 (en) Quinazolinone compounds in combined modalities for improved cancer treatment
WO2023227592A1 (en) Method for pretreating relapsing cancer